Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Theriva Biologics ( (TOVX) ) just unveiled an update.
Theriva Biologics announced key FDA guidance for a Phase 3 study of its cancer treatment VCN-01, following successful enrollment in a Phase 2b study. The FDA endorsed a stand-alone Phase 3 study design without additional chemotherapy, streamlining the path for advancing this promising therapy for metastatic pancreatic cancer. This decision aligns with Theriva’s strategy to offer new treatment options in areas of high unmet need.
Find detailed analytics on TOVX stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money